Fousseyni Traore1*, Belco Maiga1, Konimba Diabaté2, Yacaria Coulibaly3, Hawa Diall1, Pierre Togo1, Oumar Coulibaly1, Issa Amadou3, Karamoko Sacko1, Abdoul Karim Doumbia1, Abdoul Aziz Diakite1, Bakary Kamaté4, Fatoumata Dicko-Traoré1, Mariam Sylla1, Boubacar Togo1
1Gabriel Toure hospital, department of pediatrics, Bamako-Mali
2National hospital of Mali, Radiation therapy service, Bamako-Mali
3Gabriel Toure hospital, pediatric surgery service, Bamako-Mali
4Hospital of Point G, department of histopathology, Bamako-Mali
Purpose: Congenital mesoblastic nephroma (CMN) is a mesenchymal renal tumor of the newborn and young infant. This tumor is generally non-aggressive and amenable to surgical removal. Few studies are available in Africa about the treatment of CMN. The aim of this retrospective study was to evaluate the treatment of CMN in the pediatric oncology unit of teaching hospital Gabriel Toure in Bamako-Mali.
Patients and method: The study was performed retrospectively from 01 January 2005 to 31 December 2016 (duration 11 years), in the pediatric-oncology unit of Gabriel Touré Teaching Hospital. Were included, patients with histologically proven CMN. The uretero-nephrectomy was indicated for all included patients. Patients with significant tumor volume at abdominal CT-scan and those with no staging at surgery with imprecise histologic stage, received neoadjuvant and adjuvant chemotherapy, respectively.
Result:From 2005/01/01 to 2016/12/31 eight cases of CMN were included in the study. CMN accounted for 3% of renal tumors. The median age of patient was 4.5 months (1 month-6 months) with a sex ratio of 0.33 (M = 2, F = 6). Abdominal mass was the most common physical sign (n = 7; 87%). The CT scan was performed in five patients (62%). There was no difference in laterality (right kidney, n = 4, left kidney, n = 4).
Three patients received neoadjuvant chemotherapy (37%). Seventy-two percent of patients received initial nephro-ureterectomy. The histology confirmed CMN in all patients (n = 8, 100%). All patients had the classic histological form (n = 8; 100%). Stage 1 (n = 4; 50%), stage 2 (n = 2; 25%), unspecified (n = 2; 25%). Two patients received adjuvant chemotherapy (25%). Overall survival was 100% with a median follow-up of 8 years (6 -10 years).
Conclusion: Multidisciplinary collaboration is the key of therapeutic success of CMN.Read More
Madison Nation, MD1, Megyn Beyer, DO2, Margaret Ellis, DO, MSPH3, Nicholas M. Potisek, MD4*
4*Department of Pediatrics, Wake Forest Baptist Medical Center Winston-Salem, NC
University of Rhode Island
Marta Cristaldi1, Rodolfo Mauceri1, Laura Tomasello2, Giuseppe Pizzolanti2, Giovanni Zito5, Riccardo Alessandro3,4, Carla Giordano2*, Giuseppina Campisi1
1Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
2Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Laboratory of Regenerative Medicine, Section of Endocrinology, Diabetology and Metabolism, University of Palermo, Palermo, Italy
3Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics, University of Palermo, Palermo, Italy
4Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Italy
5Advanced Technologies Network (ATeN) Center, University of Palermo, Palermo, Italy
In the last three decades, the constantly increasing need for therapies, efficiently preventing and/or treating human diseases, has raised the interest in Regenerative Medicine (RM). RM is based on employing mesenchymal stem cells (MSCs), that showed to have great proliferation, self-renewal and multi-lineage differentiation potential, in vitro as well as in vivo. The opportunity of an accessible, painless and low-cost reservoir of MSCs constitutes the first important step of a successful regenerative therapy to include in the current clinical practice. Oral cavity has recently demonstrated to contain different MSCs niches: dental pulp from permanent and deciduous teeth, periodontal ligament, dental follicle, apical papilla and mucosa. MSCs from dental pulp of deciduous teeth, naturally lost in pediatric age, and the oral mucosa have shown to be easily harvested and to have a promising regenerative potential. Thus, the aim of the paper is to review the potentialities of human exfoliated deciduous teeth stem cells (SHEDs) and oral mucosa stem cells (OMSCs) in RM, with the purpose of their use as accessible source of MSCs for the future of pediatric patient.Read More
Paolo Indolfi1*, Serena Picazio2, Silverio Perrotta1, Francesca Rossi1, Andrea Pession3, Martina Di Martino1, Elvira Pota1, Daniela Di Pinto1, Roberto Rondelli3, Cristiana Indolfi1, Fiorina Casale1
1*UOSD Hemato-Oncology, Department of Woman and Children, and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, Naples, Italy
2AIL, Section “Valentina Picazio”, Caserta, Italy
3Pediatric Hemato-Oncology Unit, University of Bologna, Italy
Introduction: Childhood cancer is relatively uncommon and the European age-standardized rate was 164 new case per million per year among 0 to 15 years old children (95% CI 158-170). We analyzed data collected in the Mod. 1.01 of the AIEOP (Association Italian Pediatric Hematology-Oncology) over 25 years (1990-2014) about patients with malignant disease diagnosed in 90 towns of the “Ground of fires” (56 in Napoli and 34 in Caserta province).
Methods: Thanks to the wide monitored population we defined 5 time trends: 1990-94; 1995-99; 2000-04; 2005-09; and 2010-14. We calculated the ratio between observed cases (O) and expected (E) numbers of cases among the children from “Terra dei fuochi”.
Results: 2037 cancer patients (0-15 years) were registered in the AIEOP database: 1144 males (56.1%) and 893 females (43.8%).
Conclusions: It is note-worthy to underline that our cases needed to be integrated with the Hospital Informative System and Register of births, marriage and deaths to have a better collection of observed cases. This is a limit of our study. The data analysis do not show significant differences in number of observed cases and type of diseases respect to our previous epidemiological study on cancer cases registered in Campania.Read More
Juan R Malagelada1*, Carolina Malagelada1
1Digestive System Research Unit, University Hospital Vall d’Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain